Secondary Prevention of Cerebral Ischemia in Patent Foramen Ovale: Systematic Review and Meta-analysis

Southern Medical Journal

Volumn 94, Issue 7, 2001, Pages 699-703

  Orgera, Marisa A ^a   O'Malley, Patrick G ^a   Taylor, Allen J ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; HEART SEPTUM DEFECT; HUMAN; MALE; META ANALYSIS; MIDDLE AGED;

ADULT; ANTICOAGULANTS; BRAIN ISCHEMIA; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MALE; MIDDLE AGED; WARFARIN;

EID: 0035404696     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-200107000-00015     Document Type: Review

References (18)

1. Cabanes L, Mas JL, Cohen A, et al: Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age, a study using transesophageal echocardiography. Stroke 1993; 24:1865-1873
2. Lechat P, Mas JL, Lascault G, et al: Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318:1148-1152
3. Webster MW, Chancellor AM, Smith HJ, et al: Patent foramen ovale in young stroke patients. Lancet 1988; 2:11-12
4. Bogousslavsky J, Garazi S, Jeanrenaud X, et al: Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group. Neurology 1996; 46:1301-1305
5. Cujec B, Mainra R, Johnson DH: Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks. Can J Cardiol 1999; 15:57-64
6. Hanna JP, Sun JP, Furlan AJ, et al: Patent foramen ovale and brain infarct, echocardiographic predictors, recurrence, and prevention. Stroke 1994; 25:782-786
7. Hausmann D, Mugge A, Daniel WG: Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol 1995; 26:1030-1038
8. Mas JL, Zuber M: Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. French Study Group on Patent Foramen Ovale and Atrial Septal Aneurysm. Am Heart J 1995; 130:1083-1088
9. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188
10. Homma S, Di Tullio MR, Sacco RL, et al: Characteristics of patent foramen ovale associated with cryptogenic stroke, a biplane transesophageal echocardiographic study. Stroke 1994; 25:582-586
11. Steiner MM, Di Tullio MR, Rundek T, et al: Patent foramen ovale size and embolie brain imaging findings among patients with ischemic stroke. Stroke 1998; 29:944-948
12. Nendaz MR, Sarasin FP, Junod AF, et al: Preventing stroke recurrence in patients with patent foramen ovale: antithrombotic therapy, foramen closure, or therapeutic abstention? a decision analytic perspective. Am Heart J 1998; 135:532-541
13. Hart RG, Benavente O, McBride R, et al: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501
14. Windecker S, Wahl A. Chatterjee T, et al: Percutaneouns closure of patent foramen ovale in patieuls with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000; 101:893-898
15. Hung J, Landzberg MJ, Jenkins KJ, et al: Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol 2000; 35:1311-1316
16. Pocock SJ, Elbourne DR: Randomized trials or observational tribulations? (Editorial). N Engl J Med 2000; 342:1907-1909
17. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887-1892
18. Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342:1878-1886